Sangamo Therapeutics Stock Forecast, Price & News

Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions

Is Sangamo Therapeutics a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sangamo Therapeutics stock.
View analyst ratings for Sangamo Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Sangamo Therapeutics?

Wall Street analysts have given Sangamo Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sangamo Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Sangamo Therapeutics' next earnings date?

Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Sangamo Therapeutics.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) announced its earnings results on Thursday, August, 5th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.03. The biopharmaceutical company had revenue of $27.87 million for the quarter, compared to analyst estimates of $29.72 million. Sangamo Therapeutics had a negative trailing twelve-month return on equity of 27.99% and a negative net margin of 98.21%.
View Sangamo Therapeutics' earnings history.

How has Sangamo Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, SGMO stock has increased by 36.8% and is now trading at $9.60.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for SGMO?

4 analysts have issued 12-month target prices for Sangamo Therapeutics' shares. Their forecasts range from $16.00 to $29.00. On average, they expect Sangamo Therapeutics' share price to reach $23.00 in the next year. This suggests a possible upside of 139.6% from the stock's current price.
View analysts' price targets for Sangamo Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Sangamo Therapeutics' key executives?

Sangamo Therapeutics' management team includes the following people:

• Alexander D. Macrae, President, Chief Executive Officer & Director
• Prathyusha Durabaibu, Senior VP, Chief Financial & Accounting Officer
• R. Andrew Ramelmeier, Executive Vice President-Technical Operations
• Jason D. Fontenot, Chief Scientific Officer
• Bettina M. Cockroft, Chief Medical Officer & Senior Vice President

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics CEO Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among Sangamo Therapeutics' employees.

Who are some of Sangamo Therapeutics' key competitors?

Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Novavax (NVAX), Repligen (RGEN), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Exelixis (EXEL).
View all of SGMO's competitors.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

What is Sangamo Therapeutics' stock symbol?

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Wasatch Advisors Inc. (7.09%), BlackRock Inc. (6.80%), Vanguard Group Inc. (6.26%), State Street Corp (4.12%), JPMorgan Chase & Co. (2.25%) and Dimensional Fund Advisors LP (2.07%). Company insiders that own Sangamo Therapeutics stock include Gary Loeb, H Stewart Parker, Joseph S Zakrzewski, Rolf Andrew Ramelmeier, Saira Ramasastry and Stephen George Dilly.
View institutional ownership trends for Sangamo Therapeutics.

Which major investors are selling Sangamo Therapeutics stock?

SGMO stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, State Street Corp, Goldman Sachs Group Inc., Renaissance Technologies LLC, FMR LLC, Citadel Advisors LLC, Bank of New York Mellon Corp, and Rafferty Asset Management LLC. Company insiders that have sold Sangamo Therapeutics company stock in the last year include Gary Loeb, Rolf Andrew Ramelmeier, and Saira Ramasastry.
View insider buying and selling activity for Sangamo Therapeutics or view top insider-selling stocks.

Which major investors are buying Sangamo Therapeutics stock?

SGMO stock was acquired by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Morgan Stanley, Morgan Stanley, Northern Trust Corp, Oppenheimer & Co. Inc., and Connor Clark & Lunn Investment Management Ltd.. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski.
View insider buying and selling activity for Sangamo Therapeutics or or view top insider-buying stocks.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sangamo Therapeutics' stock price today?

One share of SGMO stock can currently be purchased for approximately $9.60.

How much money does Sangamo Therapeutics make?

Sangamo Therapeutics has a market capitalization of $1.40 billion and generates $118.19 million in revenue each year. The biopharmaceutical company earns $-121,000,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis.

How many employees does Sangamo Therapeutics have?

Sangamo Therapeutics employs 413 workers across the globe.

When was Sangamo Therapeutics founded?

Sangamo Therapeutics was founded in 1995.

What is Sangamo Therapeutics' official website?

The official website for Sangamo Therapeutics is www.sangamo.com.

Where are Sangamo Therapeutics' headquarters?

Sangamo Therapeutics is headquartered at 7000 MARINA BLVD, BRISBANE CA, 94005.

How can I contact Sangamo Therapeutics?

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at (510) 970-6000 or via email at [email protected].